These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Phage-Antibiotic Cocktail Rescues Daptomycin and Phage Susceptibility against Daptomycin-Nonsusceptible Enterococcus faecium in a Simulated Endocardial Vegetation Kunz Coyne AJ; Stamper K; El Ghali A; Kebriaei R; Biswas B; Wilson M; Deschenes MV; Tran TT; Arias CA; Rybak MJ Microbiol Spectr; 2023 Aug; 11(4):e0034023. PubMed ID: 37338375 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Werth BJ; Barber KE; Ireland CE; Rybak MJ Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Steed M; Vidaillac C; Rybak MJ Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Barber KE; Smith JR; Ireland CE; Boles BR; Rose WE; Rybak MJ Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623 [TBL] [Abstract][Full Text] [Related]
7. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Steed ME; Vidaillac C; Rybak MJ Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus. Tsai CE; Yang CJ; Chuang YC; Wang JT; Sheng WH; Chen YC; Chang SC Int J Infect Dis; 2022 Sep; 122():230-236. PubMed ID: 35640827 [TBL] [Abstract][Full Text] [Related]
10. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. Smith JR; Yim J; Raut A; Rybak MJ Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159 [TBL] [Abstract][Full Text] [Related]
11. Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model. Smith JR; Arya A; Yim J; Barber KE; Hallesy J; Singh NB; Rybak MJ Antimicrob Agents Chemother; 2016 Jul; 60(7):3970-5. PubMed ID: 27090172 [TBL] [Abstract][Full Text] [Related]
12. Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-Resistant Kunz Coyne AJ; Stamper K; Kebriaei R; Holger DJ; El Ghali A; Morrisette T; Biswas B; Wilson M; Deschenes MV; Canfield GS; Duerkop BA; Arias CA; Rybak MJ Antibiotics (Basel); 2022 Aug; 11(9):. PubMed ID: 36139953 [TBL] [Abstract][Full Text] [Related]
13. A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA). Shafiq I; Bulman ZP; Spitznogle SL; Osorio JE; Reilly IS; Lesse AJ; Parameswaran GI; Mergenhagen KA; Tsuji BT Infect Dis (Lond); 2017 May; 49(5):410-416. PubMed ID: 28116950 [TBL] [Abstract][Full Text] [Related]
14. Pre-clinical Impact of the Synergistic Mechanism of Daptomycin and Ceftaroline on Patients with Methicillin-resistant Staphylococcus aureus Bacteremia Infections. Eliazar J; Johnson T; Chbib C Curr Rev Clin Exp Pharmacol; 2021; 16(4):296-299. PubMed ID: 33423652 [TBL] [Abstract][Full Text] [Related]
15. Exploring synergistic and antagonistic interactions in phage-antibiotic combinations against ESKAPE pathogens. Kunz Coyne AJ; Eshaya M; Bleick C; Vader S; Biswas B; Wilson M; Deschenes MV; Alexander J; Lehman SM; Rybak MJ Microbiol Spectr; 2024 Oct; 12(10):e0042724. PubMed ID: 39082827 [TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Steed ME; Werth BJ; Ireland CE; Rybak MJ Antimicrob Agents Chemother; 2012 Nov; 56(11):5709-14. PubMed ID: 22908167 [TBL] [Abstract][Full Text] [Related]
18. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models. Smith JR; Barber KE; Raut A; Rybak MJ Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Steed ME; Vidaillac C; Rybak MJ Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693 [TBL] [Abstract][Full Text] [Related]
20. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. Barber KE; Werth BJ; Rybak MJ J Antimicrob Chemother; 2015 Feb; 70(2):505-9. PubMed ID: 25246437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]